Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide)  
2/6/2012 6:14:37 AM

MELBOURNE, Australia & BAAR, Switzerland--(BUSINESS WIRE)--Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has submitted a marketing authorisation application (MAA) for its first-in-class drug SCENESSE® (afamelanotide 16mg implant) to the European Medicines Agency (EMA). The MAA covers the use of SCENESSE® as a prophylactic treatment in adult patients with erythropoietic protoporphyria (EPP), a rare disease which causes absolute intolerance of patients’ skin to light.